Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer

doi:10.19401/j.cnki.1007-3639.2025.04.002

Abstract

Abstract:

Background and purpose: Epithelial ovarian cancer (EOC) has a poor prognosis and is prone to developing resistance to platinum-based chemotherapy. Exosomes are currently believed to be involved in platinum resistance in ovarian cancer. This study explored the role and mechanism of exosomes on platinum resistance of ovarian cancer. Methods: Through ultracentrifugation, exosomes were isolated and analyzed using electron microscopy, particle size studies, and Western blot for detailed exosome analysis. We detected the expression levels of exosomal proteins and related signaling pathways. Exosomal protein expression profile was analyzed by proteomics. Key differential proteins were screened by intersecting with existing drug resistance datasets. Furthermore, patients diagnosed with EOC via pathological analysis at the Fudan University Shanghai Cancer Center from August 2023 to August 2024, who underwent surgery and fulfilled the eligibility requirements, were gathered to examine the link between the expression of interferon-stimulated gene 15 (ISG15) in serum exosomes and resistance to platinum medication. The expression levels of related proteins in serum exosomes were quantitatively detected by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve was plotted to explore the predictive value of serum exosomal protein in ovarian cancer resistance. Results: Exosomes derived from platinum-sensitive and drug-resistant ovarian cancer cells were extracted and proteomic analysis was further performed. We identified 9 differential proteins associated with platinum-resistance and found the key molecule interferon-stimulated gene 15 (ISG15). Compared with sensitive cells, the expression of ISG15 in exosomes of drug-resistant ovarian cancer cells was significantly upregulated. Exosome tracer tests showed that exosomes were successfully taken up by ovarian cancer receptor cells. After coculture with drug-resistant exosomes, the expression level of ISG15 in ovarian cancer receptor cells was increased. Knockdown ISG15 in EOC cells decreased the expression of ISG15 in exosomes, and incubation of ISG15-knockdown exosomes decreased the cell viability on the condition of platinum drugs, indicating that ISG15 in exosomes regulated platinum resistance of ovarian cancer cells. Moreover, ISG15 could regulate the expression of multidrug resistance protein 1 (MDR1) through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor-kappa-light-chain-enchancer of activated B cells (NF-κB) signaling pathway. This study included a total of 87 patients. Clinical serum samples also showed that the expression of ISG15 in exosomes was higher in platinum-resistant ovarian cancer patients than in sensitive ovarian cancer patients. Using serum exosomal ISG15 as an indicator to distinguish between sensitivity and resistance, the area under ROC curve was 0.779 (P<0.05), cutoff value was 27.35ng/mL, sensitivity was 70.2%, and specificity was 76.4%. Conclusion: ISG15 in exosomes can regulate the expression of MDR1 in ovarian cancer cells through PI3K/AKT/NF-κB signaling pathway, and promote platinum resistance in ovarian cancer cells.

Key words: Ovarian cancer, Exosome, ISG15, Platinum resistance

TIAN Yanan, ZHENG Hui, YAN Tianqing, ZHANG Heng, LU Renquan, GUO Lin. Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer[J]. China Oncology, 2025, 35(4): 346-354.

Figures/Tables 6

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

References 19

[1]	SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1): 17-48.
[2]	STEWART C, RALYEA C, LOCKWOOD S. Ovarian cancer: an integrated review[J]. Semin Oncol Nurs, 2019, 35(2): 151-156. doi: S0749-2081(19)30012-9 pmid: 30867104
[3]	LI B L, LU W, QU J J, et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis[J]. J Cell Physiol, 2019, 234(3): 2943-2953.
[4]	DOYLE L M, WANG M Z. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis[J]. Cells, 2019, 8(7): 727.
[5]	ZHANG Y, BI J Y, HUANG J Y, et al. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications[J]. Int J Nanomedicine, 2020, 15: 6917-6934.
[6]	LIU Y X, ZHU K Y, GUAN X L, et al. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer[J]. J Ovarian Res, 2021, 14(1): 128. doi: 10.1186/s13048-021-00884-z pmid: 34598710
[7]	ZHENG H, ZHANG M Q, MA S, et al. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients[J]. Cancer Med, 2020, 9(14): 5200-5209.
[8]	LIU J, ZHU M Y, FENG Y, et al. The multidrug resistance can be reversed for the decrease of P-gp and LRP by inhibiting PI3K/AKT/NF-κB signal pathway in nasopharynx carcinoma[J]. Biosci Rep, 2020, 40(5): BSR20190239.
[9]	SANDERCOCK J, PARMAR M B, TORRI V, et al. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence[J]. Br J Cancer, 2002, 87(8): 815-824.
[10]	ROMA-RODRIGUES C, FERNANDES A R, BAPTISTA P V. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells[J]. Biomed Res Int, 2014, 2014: 179486.
[11]	MAIORINO L, DAßLER-PLENKER J, SUN L J, et al. Innate immunity and cancer pathophysiology[J]. Annu Rev Pathol, 2022, 17: 425-457.
[12]	PADARIYA M, SZNARKOWSKA A, KOTE S, et al. Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes[J]. Biomolecules, 2021, 11(5): 622.
[13]	NGUYEN H M, GAIKWAD S, OLADEJO M, et al. Interferon stimulated gene 15 (ISG15) in cancer: an update[J]. Cancer Lett, 2023, 556: 216080.
[14]	PERNG Y C, LENSCHOW D J. ISG15 in antiviral immunity and beyond[J]. Nat Rev Microbiol, 2018, 16(7): 423-439.
[15]	DESAI S D, WOOD L M, TSAI Y C, et al. ISG15 as a novel tumor biomarker for drug sensitivity[J]. Mol Cancer Ther, 2008, 7(6): 1430-1439. doi: 10.1158/1535-7163.MCT-07-2345 pmid: 18566215
[16]	CHEN R H, DU Y, HAN P, et al. ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma[J]. Oncotarget, 2016, 7(13): 16910-16922.
[17]	DORAYAPPAN K D P, WAGNER V, PARK D, et al. ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis[J]. J Extracell Biol, 2024, 3(2): e92. doi: 10.1002/jex2.92 pmid: 38939897
[18]	OYAMA Y, SHIGETA S, TOKUNAGA H, et al. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: a potential role of CHD4 inhibition as a combination therapy with platinum agents[J]. PLoS One, 2021, 16(6): e0251079.
[19]	QIU F H, HOU T Y, HUANG D H, et al. Evaluation of two high-abundance protein depletion kits and optimization of downstream isoelectric focusing[J]. Mol Med Rep, 2015, 12(5): 7749-7755. doi: 10.3892/mmr.2015.4417 pmid: 26460178